Paul J. Molino

Paul J. Molino is a highly experienced patent litigator and a founding and co-managing partner at Rakoczy Molino Mazzochi Siwik LLP (RMMS). He is widely recognized for his expertise in handling complex patent infringement litigation, with a primary focus on the pharmaceutical and chemical industries. His practice encompasses a deep understanding of Hatch-Waxman statutory patent infringement actions, as well as counseling on patent prosecution and strategic intellectual property rights.

Molino primarily represents generic pharmaceutical companies, consistently taking on the defendant's side in high-stakes litigation against brand-name drug owners in Hatch-Waxman and Biologics Price Competition and Innovation Act (BPCIA) cases. His firm, RMMS, specializes exclusively in pharmaceutical patent and regulatory counseling and litigation. The single tracked case, Haemonetics Corporation v. Fresenius Kabi USA, LLC et al., aligns with his firm's focus on life sciences, where he represents the defendant.

Throughout his career, Mr. Molino has been involved in significant patent litigation outcomes. He assisted in securing a final judgment of invalidity at the Federal Circuit for GlaxoSmithKline's Paxil® patent, a victory that gained national attention. He also contributed to two district court judgments of noninfringement for his pharmaceutical clients in the Neurontin® (gabapentin) litigation. Further, he served as a lead trial attorney in successful bench trials for Lupin involving Trizivir® and gatifloxacin ophthalmic solution, with the latter affirmed by the Federal Circuit.

In addition to federal court litigation, Mr. Molino routinely handles pharmaceutical cases before the U.S. Patent and Trademark Office, indicating experience with PTAB and IPR proceedings. He earned his J.D. from DePaul University and holds a Bachelor of Science in Pharmacy from Drake University College of Pharmacy. He is admitted to practice in Illinois, before the U.S. Patent and Trademark Office, and in the U.S. Courts of Appeals for the Federal and Seventh Circuits.